Pazopanib: An antiangiogenic drug in perspective

Carlos A. Castaneda, Henry L. Gomez

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway. It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.

Original languageEnglish
Pages (from-to)1335-1348
Number of pages14
JournalFuture Oncology
Issue number9
StatePublished - 2009


  • Angiogenesis
  • Breast
  • Cervix
  • Glyomas
  • Lung
  • Multiple myeloma
  • Ovarian
  • Pazopanib
  • Renal
  • Sarcomas
  • Thyroid
  • Tyrosine kinase
  • VEGF


Dive into the research topics of 'Pazopanib: An antiangiogenic drug in perspective'. Together they form a unique fingerprint.

Cite this